Drug delivery by erythrocytes: “Primum non nocere”

Villa, Carlos H.; Seghatchian, Jerard; Muzykantov, Vladimir R.

doi:10.1016/j.transci.2016.10.017

Cited by 39 publications

(25 citation statements)

References 47 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emergence of stem-cell derived RBCs provides further opportunities for developing customized antibody delivery systems for immune therapy [13]. Currently, several drug-loading techniques such as encapsulation and surface conjugation have been used for the effective treatment of infections, cancer, and chronic autoimmune diseases [13]. More recently, there is progressive evolution in the use of inhalable drug delivery systems for lung cancer therapy.…”

Section: Ccp Iii) Affinity Column Preparation Of Antibody Hyperconcementioning

confidence: 99%

“…With well-established protocols for their safe collection, processing and storage this makes RBCs readily available to be used as delivery systems. The emergence of stem-cell derived RBCs provides further opportunities for developing customized antibody delivery systems for immune therapy [ 13 ]. Currently, several drug-loading techniques such as encapsulation and surface conjugation have been used for the effective treatment of infections, cancer, and chronic autoimmune diseases [ 13 ].…”

Section: Alternative Sources Of Covid-19 Antibodies For Clinical Usementioning

confidence: 99%

See 1 more Smart Citation

Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

Seghatchian

Acker

Putter

2020

Transfusion and Apheresis Science

Self Cite

View full text Add to dashboard Cite

COVID-19 convalescent plasma (CCP) therapy involves the use of circulating antibodies administration from recovered COVID 19 patients as a practical strategy to provide immediate passive immunity in susceptible recipients in need. Global concern over the potential for "second" or "third" waves of infection to occur before effective vaccines or drug therapies are available has many looking at other biological sources for large-scale production of neutralizing SARS-CoV-2 antibodies. This report summarizes some of the novel strategies for developing alternative safe sources of therapeutic autologous antibodies from COVID-19 infected patients, and provides some original thoughts on how to rapidly implement a safe passive immunity in those COVID-19 patients who are most in need of intervention. COVID-19 antibodies can be isolated or delivered using a number of other techniques including: plasmapheresis, plasma cryoprecipitate reduced (cryosupernatant), antibody hyperconcentrates and advanced cell-based delivery systems. While these proposed technological options may, in some cases, be theoretical, the growing concern over the rapid spread of the SARS-CoV-2 virus has prompted many to pursue innovative and creative solutions to reduce the mortality and morbidity resulting from the current global pandemic. A comparative analysis of various strategies currently in use deserved exploring and this highlighted separately as the essential part of this concise theme.

show abstract

Section: Ccp Iii) Affinity Column Preparation Of Antibody Hyperconcementioning

confidence: 99%

Section: Alternative Sources Of Covid-19 Antibodies For Clinical Usementioning

confidence: 99%

Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

Seghatchian

Acker

Putter

2020

Transfusion and Apheresis Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…The entrance of MPPs alters the membrane, making it susceptible to physiological and pathological changes that RBCs generally confront while circulation. Majority of MPPs are cationic in nature which may interact with glycocalyx of RBCs thereby, producing undesirable effects such as pro-inflammatory response to endothelium (Villa et al 2016).…”

Section: Encapsulation Of Nanoparticle In Rbcsmentioning

confidence: 99%

Red blood cells as an efficient in vitro model for evaluating the efficacy of metallic nanoparticles

et al. 2019

View full text Add to dashboard Cite

Blood and the linings of blood vessels may be regarded as a fifth tissue type. The human body contains 5 × 10 9 red blood cells (RBCs) per ml, a total of 2.5 × 10 13 cells in the 5 l of blood present in the body. With an average lifetime of 125 days, human RBCs are destroyed by leukocytes in the spleen and liver. Nowadays red blood cells are extensively used to study various metabolic functions. Nanoparticles (NP) are being widely accepted for drug delivery system. This review summarizes the red blood cells, NPs and their characteristics on the basis of the RBC components along with drug delivery systems through RBCs. Further, we also discussed that how erythrocytes can be used as an efficient in vitro model for evaluating the efficacy of various nanocomposite materials.

show abstract

“… 32 , 33 Therefore, biocompatibility and other adverse effects (drug pharmacokinetics, distribution, and interaction) should be consistently and singularly analyzed. 31 , 34 …”

Section: Discussionmentioning

confidence: 99%

<p>Novel Fast and Reliable Method for Nano-Erythrosome Production Using Shear Force</p>

Capossela¹,

Mathew²,

Boos³

et al. 2020

DDDT

View full text Add to dashboard Cite

Purpose The production of nano-erythrosomes (NEs) by extrusion, which is considered the “gold standard”, has several disadvantages such as difficult equipment assembly, long procedure time, variable pressure, and problems with sterility. An alternative approach, using ultrasound probe, has been shown to overheat the sample and have suboptimal results compared to the extrusion method. In our study, we propose, develop, and test a new method for the fabrication of NEs based on shear force and then compare it to the “gold standard” extrusion approach. Methods The new method consists of mechanical shear force disruption of the hemoglobin-depleted erythrocyte ghost membranes, with the aid of a rotor stator based tissue homogenizer. Using the same batches of erythrocyte ghost membranes, we compared NEs produced by shear force to NEs produced by the well-established extrusion approach. NEs were characterized for yield, size, encapsulation efficiency, morphology, and stability by flow cytometry (FC), transmission electron microscopy (TEM), and zeta potential analysis. Results The shear force based process was easier to set up, significantly faster, had better sterility control, and decreased variability between batches. The shear force method generated NEs with the desired size distribution (particles diameter ~125 nm), which were morphologically and functionally equivalent to the NEs produced by extrusion. NEs produced by shear force were stable in terms of counts, size, and fluorescence intensity for 3 weeks at +4°C. Moreover, they showed colloidal stability and minimal influence to centrifugal stress, turbulence shock, and hemolytic potential. Conclusion The newly proposed shear force method allows faster, easier, and highly reproducible NEs production when compared to the conventional extrusion approach. The new setup allows simultaneous production of sterile batches of NEs, which have homogenous size distribution, good stability, and improved shelf life storage. The ability of the shear force method to process also high concentration samples indicates a future potential development of large-scale NEs production and industrial application, which has been a challenge for the extrusion method.

show abstract

Drug delivery by erythrocytes: “Primum non nocere”

Cited by 39 publications

References 47 publications

Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

Red blood cells as an efficient in vitro model for evaluating the efficacy of metallic nanoparticles

<p>Novel Fast and Reliable Method for Nano-Erythrosome Production Using Shear Force</p>

Contact Info

Product

Resources

About